A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor biological treatments according to the current guidelines

Publication:
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor biological treatments according to the current guidelines

dc.contributor.author	Temel, M
dc.date.accessioned	2022-03-02T05:49:08Z
dc.date.accessioned	2026-01-11T13:15:10Z
dc.date.available	2022-03-02T05:49:08Z
dc.date.issued	2005-09-01
dc.identifier.doi	10.1136/ard.2004.028423
dc.identifier.issn	0003-4967
dc.identifier.issue	9
dc.identifier.pages	1383-1384
dc.identifier.uri	https://hdl.handle.net/11424/219005
dc.identifier.volume	64
dc.language.iso	eng
dc.relation.uri	https://ard.bmj.com/lookup/doi/10.1136/ard.2004.028423
dc.title	A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor biological treatments according to the current guidelines
dc.type	article
dspace.entity.type	Publication

Now showing 1 - 1 of 1